Research programme: nicotinamide adenine dinucleotide modulators - Mitobridge

Drug Profile

Research programme: nicotinamide adenine dinucleotide modulators - Mitobridge

Alternative Names: NAD+ modulators - Mitobridge

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ecole Polytechnique Federale de Lausanne.
  • Developer Ecole Polytechnique Federale de Lausanne.; Mitobridge
  • Class
  • Mechanism of Action Nicotinamide adenine dinucleotide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mitochondrial disorders

Most Recent Events

  • 18 Sep 2017 Mitobridge in-licenses intellectual property from École polytechnique fédérale de Lausanne
  • 18 Sep 2017 Mitobridge’s NAD+ modulation patent portfolio includes composition of matter patent applications
  • 18 Sep 2017 Preclinical trials in Mitochondrial disorders in USA (PO) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top